News Sentiment

PRQR sentiment intelligence

ProQR Therapeutics BV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.73 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.4% over one week, +20.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -4.4% Price reacting lower
Trend fit Trend inactive 20.1% over four weeks
Fair value -13.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 7
TradingView 6
MT Newswires 3
MarketBeat 2
GuruFocus 2
Seeking Alpha 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Analyst action 6
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Barchart.com Direct company coverage

Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap

The Retinitis Pigmentosa market is projected to experience significant growth by 2034, driven by increasing prevalence, awareness, and the launch of multiple pipeline products from companies like SparingVision SAS, ProQR Therapeutics NV, and Ocugen. Key developments include Ocuge

Tone
Positive 65/100
Event
Earnings
Published
25 Jun 2026 12:11
Source
Barchart.com
Investing.com Direct company coverage

ProQR prices $50M stock offering at $1.81 per share

ProQR Therapeutics N.V. is pricing an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $50 million. Concurrently, Eli Lilly and Company, an existing partner, will purchase an additional 5,100,780 ordinary shar

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 12:11
Source
Investing.com